Shares Of Conatus Pharmaceuticals End The Day Up 17% After Company Reported Positive Phase 2 Results In NASH
March 26, 2015 at 19:41 PM EDT
Conatus announced that NASH Trial met the primary endpoint of the clinical trial, and shares jumped as much as 40% before settling.
